HARMONY BIOSCIENCES HOLDINGS, INC. Amortization of Intangible Assets
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Amortization of Intangible Assets of $5.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $5.96M, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $5.96M, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $5.96M, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $5.96M, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for fiscal 2025 was $23.84M, a 0.00% change from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for fiscal 2024 was $23.84M, a 0.00% change from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for fiscal 2023 was $23.84M, a 3.83% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. amortization of intangible assets for fiscal 2022 was $22.97M, a 24.65% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.96M 10-Q · filed 2026-08-04 | $11.92M 10-Q · filed 2026-08-04 | $17.88M derived: sum of 3 quarters · filed 2026-08-04 | $23.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $5.96M 10-Q · filed 2026-05-07 | $11.92M derived: sum of 2 quarters · filed 2026-05-07 | $17.88M derived: sum of 3 quarters · filed 2026-05-07 | $23.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.92M derived: sum of 2 quarters · filed 2026-02-24 | $17.88M derived: sum of 3 quarters · filed 2026-08-04 | $23.84M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $5.96M 10-Q · filed 2025-11-04 | $11.92M derived: sum of 2 quarters · filed 2026-08-04 | $17.88M 10-Q · filed 2025-11-04 | $23.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $5.96M 10-Q · filed 2026-08-04 | $11.92M 10-Q · filed 2026-08-04 | $17.88M derived: sum of 3 quarters · filed 2026-08-04 | $23.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $5.96M 10-Q · filed 2026-05-07 | $11.92M derived: sum of 2 quarters · filed 2026-05-07 | $17.88M derived: sum of 3 quarters · filed 2026-05-07 | $23.84M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.92M derived: sum of 2 quarters · filed 2026-02-24 | $17.88M derived: sum of 3 quarters · filed 2026-02-24 | $23.84M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $5.96M 10-Q · filed 2025-11-04 | $11.92M derived: sum of 2 quarters · filed 2025-11-04 | $17.88M 10-Q · filed 2025-11-04 | $23.84M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $5.96M 10-Q · filed 2025-08-05 | $11.92M 10-Q · filed 2025-08-05 | $17.88M derived: sum of 3 quarters · filed 2026-02-24 | $23.84M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $5.96M 10-Q · filed 2025-05-06 | $11.92M derived: sum of 2 quarters · filed 2026-02-24 | $17.88M derived: sum of 3 quarters · filed 2026-02-24 | $23.84M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.92M derived: sum of 2 quarters · filed 2026-02-24 | $17.88M derived: sum of 3 quarters · filed 2026-02-24 | $23.84M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $5.96M 10-Q · filed 2024-10-29 | $11.92M derived: sum of 2 quarters · filed 2024-10-29 | $17.88M 10-Q · filed 2024-10-29 | $23.84M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $5.96M 10-Q · filed 2024-08-06 | $11.92M 10-Q · filed 2024-08-06 | $17.88M derived: sum of 3 quarters · filed 2025-02-25 | $23.84M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $5.96M 10-Q · filed 2024-04-30 | $11.92M derived: sum of 2 quarters · filed 2025-02-25 | $17.88M derived: sum of 3 quarters · filed 2025-02-25 | $23.84M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $11.92M derived: sum of 2 quarters · filed 2025-02-25 | $17.88M derived: sum of 3 quarters · filed 2025-02-25 | $22.97M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $5.96M 10-Q · filed 2023-10-31 | $5.96M 10-Q · filed 2022-11-01 | $11.92M derived: sum of 2 quarters · filed 2023-10-31 | $17.00M 10-Q · filed 2023-10-31 | $21.65M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $5.96M 10-Q · filed 2023-08-01 | $11.04M 10-Q · filed 2023-08-01 | $15.69M derived: sum of 3 quarters · filed 2024-02-22 | $20.26M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $5.08M 10-Q · filed 2023-05-02 | $9.72M derived: sum of 2 quarters · filed 2024-02-22 | $14.30M derived: sum of 3 quarters · filed 2024-02-22 | $18.93M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $9.22M derived: sum of 2 quarters · filed 2024-02-22 | $13.85M derived: sum of 3 quarters · filed 2024-02-22 | $18.42M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $4.57M 10-Q · filed 2022-11-01 | $9.20M derived: sum of 2 quarters · filed 2022-11-01 | $13.78M 10-Q · filed 2022-11-01 | $18.06M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $4.63M 10-Q · filed 2022-08-02 | $9.21M 10-Q · filed 2022-08-02 | $13.49M derived: sum of 3 quarters · filed 2023-02-21 | $15.36M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $4.58M 10-Q · filed 2022-05-03 | $8.86M derived: sum of 2 quarters · filed 2023-02-21 | $10.73M derived: sum of 3 quarters · filed 2023-02-21 | $12.64M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $6.15M derived: sum of 2 quarters · filed 2023-02-21 | $8.06M derived: sum of 3 quarters · filed 2023-02-21 | $9.84M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $1.87M 10-Q · filed 2021-11-09 | $3.77M derived: sum of 2 quarters · filed 2021-11-09 | $5.56M 10-Q · filed 2021-11-09 | $7.41M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $1.91M 10-Q · filed 2021-08-10 | $3.69M 10-Q · filed 2021-08-10 | $5.54M derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $1.79M 10-Q · filed 2021-05-11 | $3.64M derived: sum of 2 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.81M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $965.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |